RU93052390A - Способ лечения шизофрении, применение комбинации арахидоновой и докозагексановой кислот для получения лекарственного средства для лечения шизофрении - Google Patents

Способ лечения шизофрении, применение комбинации арахидоновой и докозагексановой кислот для получения лекарственного средства для лечения шизофрении

Info

Publication number
RU93052390A
RU93052390A RU93052390/14A RU93052390A RU93052390A RU 93052390 A RU93052390 A RU 93052390A RU 93052390/14 A RU93052390/14 A RU 93052390/14A RU 93052390 A RU93052390 A RU 93052390A RU 93052390 A RU93052390 A RU 93052390A
Authority
RU
Russia
Prior art keywords
schizophrenia
docosahexane
arahidonic
combination
medicine
Prior art date
Application number
RU93052390/14A
Other languages
English (en)
Other versions
RU2123844C1 (ru
Inventor
Фредерик Хорробин Дэвид
Original Assignee
Скотиа Холдингс ПЛС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929224809A external-priority patent/GB9224809D0/en
Application filed by Скотиа Холдингс ПЛС filed Critical Скотиа Холдингс ПЛС
Publication of RU93052390A publication Critical patent/RU93052390A/ru
Application granted granted Critical
Publication of RU2123844C1 publication Critical patent/RU2123844C1/ru

Links

Claims (1)

  1. Предложенная комбинация арахидоновой и докозагексановой кислот может быть использована для лечения шизофрении с негативными симптомами и/или для лечения нарушений, связанных с присутствием низких уровней НЖК в клеточных мембранах.
RU93052390A 1992-11-26 1993-11-25 Способ лечения шизофрении RU2123844C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9224809.5 1992-11-26
GB929224809A GB9224809D0 (en) 1992-11-26 1992-11-26 Schizophrenia

Publications (2)

Publication Number Publication Date
RU93052390A true RU93052390A (ru) 1996-10-10
RU2123844C1 RU2123844C1 (ru) 1998-12-27

Family

ID=10725730

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93052390A RU2123844C1 (ru) 1992-11-26 1993-11-25 Способ лечения шизофрении

Country Status (19)

Country Link
US (1) US5516800A (ru)
EP (2) EP0733360A3 (ru)
JP (1) JPH06199663A (ru)
CN (1) CN1104494A (ru)
AT (1) ATE144706T1 (ru)
AU (2) AU666782B2 (ru)
CA (1) CA2109777A1 (ru)
DE (1) DE69305723T2 (ru)
DK (1) DK0599576T3 (ru)
ES (1) ES2093935T3 (ru)
GB (1) GB9224809D0 (ru)
GR (1) GR3021692T3 (ru)
HK (1) HK114297A (ru)
MY (1) MY109905A (ru)
NO (1) NO934266L (ru)
NZ (1) NZ250265A (ru)
RU (1) RU2123844C1 (ru)
SG (1) SG47838A1 (ru)
ZA (1) ZA938835B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
ATE264099T1 (de) * 1993-06-09 2004-04-15 Martek Biosciences Corp Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
GB9510636D0 (en) * 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
EP1886679A3 (en) * 1995-06-07 2008-05-28 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
PT956013E (pt) 1996-10-11 2003-08-29 Scarista Ltd Preparacao farmaceutica compreendendo acido eicosapentaenoico e/ou acido estearidonico
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
DE69935995T3 (de) * 1998-10-15 2011-02-10 Dsm Ip Assets B.V. Polyungesättigen fettsäuren nährungsergänzung
GB9826899D0 (en) * 1998-12-08 1999-01-27 Knoll Ag Methods to treat depression and other psychiatric disorders and assays for compounds
AU3119600A (en) * 1998-12-15 2000-07-03 American Home Products Corporation Method and composition for the maintenance and restitution of gut integrity
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
EP1427407A4 (en) 2001-03-23 2005-05-11 Luitpold Pharm Inc CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS
EP1423107B1 (en) * 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
CA2551882A1 (en) * 2004-01-19 2005-08-11 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
US8637321B2 (en) * 2005-10-24 2014-01-28 Duke University Lipidomics approaches for central nervous system disorders
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
KR101578498B1 (ko) 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 신경 재생제
EP2211881A4 (en) * 2007-11-01 2012-01-04 Wake Forest University School Of Medicine COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AFFECTING MAMMALS
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB2460056A (en) * 2008-05-14 2009-11-18 Arab Science & Technology Foun Compositions comprising omega-6 fatty acids for use in treating schistosomiasis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882352A (en) * 1986-07-28 1989-11-21 Nelson Research & Development Co. Method for treating schizophrenia
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
US4588721A (en) * 1983-09-12 1986-05-13 The Upjohn Company Treatment of negative symptoms of schizophrenia
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
GB8603621D0 (en) * 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
GB8715914D0 (en) * 1987-07-07 1987-08-12 Efamol Ltd Treatment of cerabral disorders
FR2619712B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
DE3920679A1 (de) * 1989-06-23 1991-01-10 Milupa Ag Fettmischung zur herstellung von nahrungen, insbesondere saeuglingsnahrungen
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
US5070101A (en) * 1991-02-14 1991-12-03 Mount Sinai School Of Medicine Of The City University Of New York Method and pharmaceutical composition for the treatment of schizophrenia

Similar Documents

Publication Publication Date Title
RU93052390A (ru) Способ лечения шизофрении, применение комбинации арахидоновой и докозагексановой кислот для получения лекарственного средства для лечения шизофрении
EP0733360A3 (en) Use of a combination of arachidonic acid and dosohexaenoic acid in the preparation of e medicament for treating cell membrane abnormalities due to low C20 or C22 essential fatty acids
DE69312579T2 (de) Arzneimittel zur Behandlung von Vulva-Dystrophie oder Vaginaltrockenheit
GB2068947B (en) Waste water treatment in the production of methacrylic acid
CA2071215A1 (en) Method and composition for treating inflammatory bowel disorders
FR2554814B1 (fr) Oxazolidines, procede pour leur preparation et leurs utilisations therapeutiques, notamment dans le traitement de l'obesite et du diabete
DE69005062T2 (de) Fettsäuren zur Behandlung und Prävention von Hautschäden durch Radiotherapie.
IT1189298B (it) Procedimento per produrre i glicosa minoglicani dermatansolfato ed eparan-solfato sostanzialmente puri e loro impiego farmaceutico
DE3874107T2 (de) Reinigung von Essigsäure durch Behandeln mit Ozon.
JPS6427A (en) Medicine acting on heart and heart blood system and its production
MA21046A1 (fr) Procede destine au traitement complementaire de solutions aqueuses d'acide fluosilicique .
GR3006674T3 (ru)
ATE160090T1 (de) Verwendung von l-carnitine und acyl-l-carnitinen zur behandlung von patienten die an aids- verwandten syndromen leiden und von asymptomatischen hiv-seropositiven patienten
YU47599B (sh) Postupak za prečišćavanje vodenog n-metilmorfolin-n-oksidnog rastvora
DE3773059D1 (de) Ester von salsalat mit guajakol zur behandlung von phlogistischen bronchopneumopathien.
ATE19855T1 (de) Pharmazeutische und diaetetische zusammensetzung.
FR2656528B1 (fr) Formule combinee de cimetidine-pirenzepine pour le traitement des ulceres simples de l'estomac et des erosions et procede de traitement.
FR2612774B1 (fr) Compositions cosmetiques et pharmaceutiques, utilisees pour traiter le processus de l'alopecie androgenogenetique, contenant de l'acide azelaique
RU93032043A (ru) Способ лечения конъюктивита
FR2621578B1 (fr) Procede de dissolution reductrice du puo2, utilisable notamment pour le traitement de dechets organiques contamines par puo2
RU92012802A (ru) Способ лечения стоматитов
ES8105392A1 (es) Procedimiento de obtencion de una solucion de aminoacidos y peptidos de origen animal por proceso enzimatico
ES8500055A1 (es) Procedimiento para la obtencion de un medicamento a base de un derivado de pirazolinona.
RU97112310A (ru) Способ лечения язвенной болезни
RU95116093A (ru) Способ лечения больных с острыми экзо- и эндотоксикозами